LEIDEN, THE NETHERLANDS--(Marketwired - August 29, 2013) - Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that
it decided to redeem the seventh and final tranche of its EUR16.35 million
convertible bond for cash. A total of EUR 2,354,465 will be paid in cash to
the bondholders on 1 October 2013 under the terms and conditions of the
bond, serving as a final redemption and interest payment.
Yesterday, as the (also final) balancing payment for the redemption of the
6(th) tranche, 827,347 shares were issued to the Bondholders. As result of
this issuance, the number of outstanding shares has increased from
229,042,869 to 229,870,216.
About the January 2013 Convertible Bonds
As announced in our press release on 16 January 2013, and following the
approval of the increase of the Company's authorized share capital during
the extraordinary general meeting of shareholders, which was held on
February 28, 2013, Pharming will redeem the bond in full on a month by
month basis in seven equal tranches, such that the bond will be redeemed in
full on 1 October 2013. Pharming can decide at its discretion to redeem the
bond and pay the interest due, by means of monthly equity tranches or cash
payments. The remaining redemption date for this last tranche is 1 October.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of
unmet medical needs. RUCONEST® (conestat alfa) is a recombinant human
C1 esterase inhibitor approved for the treatment of angioedema attacks in
patients with HAE in all 27 EU countries plus Norway, Iceland and
Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum.
RUCONEST® is partnered with Santarus, Inc. (NASDAQ: SNTS) in North
America and a Biologics License Application (BLA) for RUCONEST® is
under review by the U.S. Food and Drug Administration. The product is also
being evaluated for various follow-on indications. Pharming has a unique
GMP compliant, validated platform for the production of recombinant human
proteins that has proven capable of producing industrial volumes of high
quality recombinant human protein in a more economical way compared to
current cell based technologies. In July 2013, the Platform was partnered
with Shanghai Institute for Pharmaceutical Industry (SIPI), a Sinopharm
Company, for joint global development of new products. Pre-clinical
development and manufacturing will take place at SIPI and are funded by
SIPI. Pharming and SIPI initially plan to utilise this platform for the
development of rhFVIII for the treatment of Haemophilia A. Additional
information is available on the Pharming website, www.pharming.com.
This press release contains forward looking statements that involve known
and unknown risks, uncertainties and other factors, which may cause the
actual results, performance or achievements of the Company to be materially
different from the results, performance or achievements expressed or
implied by these forward looking statements.
Press release (PDF):
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE